Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Overweight on Cellectis, Lowers Price Target to $7

Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and lowers the price target from $9 to $7.
byBenzinga Newsdesk
May 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and lowers the price target from $9 to $7.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0